Evidence map›Paper›PMID 42851504›Full record

ArticleFrontiers in pharmacology2026

Yuting Zhao, Jing Zeng, Guanglong Pang, Ying Wu, Shuzhi Wang, Zhengwen Lei, Xiangyong Hao, Yaxin Chen, Chengxuan Hu, Xianlin Zeng and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Yuting Zhao *School of Basic Medicine, School of Pharmaceutical Science, Hengyang Medical School, University of South China, Hengyang, Hunan, China.
Jing Zeng *School of Basic Medicine, School of Pharmaceutical Science, Hengyang Medical School, University of South China, Hengyang, Hunan, China.
Guanglong Pang *School of Basic Medicine, School of Pharmaceutical Science, Hengyang Medical School, University of South China, Hengyang, Hunan, China.
Ying WuSchool of Basic Medicine, School of Pharmaceutical Science, Hengyang Medical School, University of South China, Hengyang, Hunan, China.
Shuzhi WangSchool of Basic Medicine, School of Pharmaceutical Science, Hengyang Medical School, University of South China, Hengyang, Hunan, China.
Zhengwen LeiDepartment of Thoracic and Cardiovascular Surgery, The First Affiliated Hospital, Hengyang Medical School, University of South China, Hengyang, Hunan, China.
Xiangyong HaoDepartment of General Surgery, Gansu Provincial Hospital, Lanzhou, China.
Yaxin ChenSchool of Basic Medicine, School of Pharmaceutical Science, Hengyang Medical School, University of South China, Hengyang, Hunan, China.
Chengxuan HuSchool of Basic Medicine, School of Pharmaceutical Science, Hengyang Medical School, University of South China, Hengyang, Hunan, China.
Xianlin ZengSchool of Basic Medicine, School of Pharmaceutical Science, Hengyang Medical School, University of South China, Hengyang, Hunan, China.
Xinyan HuangHengyang Traditional Chinese Medicine Hospital, Hengyang, Hunan, China.
Xinlin ZhongHengyang Traditional Chinese Medicine Hospital, Hengyang, Hunan, China.
Zhen WangSchool of Basic Medicine, School of Pharmaceutical Science, Hengyang Medical School, University of South China, Hengyang, Hunan, China.
Xue PengSchool of Basic Medicine, School of Pharmaceutical Science, Hengyang Medical School, University of South China, Hengyang, Hunan, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Doxorubicin (DOX) is a broad-spectrum antineoplastic agent with remarkable efficacy against various malignant tumors. However, its clinical application is severely limited by profound hepatotoxicity, wherein oxidative stress acts as a pivotal mechanism underlying DOX-induced hepatotoxicity.

Indexed as

DOX-induced hepatotoxicitydoxorubicinN-salicyloyl tryptamine derivativesoxidative stressPI3K/AKT/HO-1

Identifiers

PMID42851504
PMCPMC13646450

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.